At Vaxcyte, we are driven by our:
Bold Goal
To prevent or treat infections caused by bacterial diseases such as pneumococcal disease, Group A Strep and periodontitis.
Sense of Urgency
Bacterial infections remain one of the greatest public health challenges of the 21st century.
Vast Opportunity
Re-engineering the way complex vaccines are
made by leveraging our advanced chemistry platform that goes beyond conventional vaccine development approaches.
Singular Focus
We are on a global mission to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases.
“Not since the 1950s has vaccine innovation been as relevant as today. Vaccines are now recognized for the true value they bring in protecting all of us from serious diseases.”
Jim Wassil, Executive Vice President and Chief Operating Officer

Eliminating Invasive Bacterial Infections
Despite renewed interest in vaccine innovation, bacterial infectious diseases have not historically received adequate attention. The global incidence of pneumococcal disease remains high, driven in part by emerging serotypes not covered by currently available vaccines. Our site-specific conjugation technology allows us to engineer broader-spectrum pneumococcal conjugate vaccines (PCVs) that we believe may enable our PCV franchise to surpass the coverage of other pneumococcal vaccines and provide greater disease protection, while maintaining effectiveness.